In Germany and Switzerland, more biosimilars were marketed and at lower prices than in the US between 2011 and 2020, finds a JAMA Network Open article [1].
More >US vs Germany and Switzerland: US biosimilars market lags with higher prices
Biosimilars/Research
|
Posted 27/01/2023
0
FORO LATINOAMERICANO DE ESTA SEMANA
Guidelines for the regulation of biologicals, biosimilars and radiopharmaceuticals in Brazil
Posted 01/12/2022
ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Survei...
Totality of evidence for biosimilar pegfilgrastim Ziextenzo
Posted 09/09/2022
Agarwala et al. have recently published a review on the totality of evidence (ToE)...
Regulatory landscape for biosimilars in Latin America
Posted 09/09/2022
The biosimilar regulatory situation in Latin America varies broadly among the different...
Guidelines for the regulation of biologicals, biosimilars and radiopharmaceuticals in Brazil
Posted 01/12/2022
ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Survei...
Totality of evidence for biosimilar pegfilgrastim Ziextenzo
Posted 09/09/2022
Agarwala et al. have recently published a review on the totality of evidence (ToE)...
Regulatory landscape for biosimilars in Latin America
Posted 09/09/2022
The biosimilar regulatory situation in Latin America varies broadly among the different...
Home/Non‐Biological Complex Drugs
FDA issues final guidance on liposome drug products
Posted 27/04/2018
0
On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...
More >
